Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249106 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults
A Phase 1 study, sponsored by International AIDS Vaccine Initiative.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00249106 is a Phase 1 study that has completed, run by International AIDS Vaccine Initiative. The registered enrollment target is 45 participants.
The verdict
NCT00249106, a Phase 1 study, has completed, sponsored by International AIDS Vaccine Initiative.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and immune response to a investigational DNA Plasmid HIV vaccine, ADVAX e/g + ADVAX p/n-t (ADVAX), at three different dosage levels, in adults who are not infected with HIV.
Interventions
- BIOLOGICAL ADVAX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00249106
The ClinicalTrials.gov registry entry for NCT00249106 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADVAX is the first listed.
NCT00249106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00249106 about?
NCT00249106 is a clinical study titled "Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults". The purpose of this study is to determine the safety and immune response to a investigational DNA Plasmid HIV vaccine, ADVAX e/g + ADVAX p/n-t (ADVAX), at three different dosage levels, in adults who are not infected with HIV.
What is the current status of trial NCT00249106?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2003-12. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00249106?
The interventions under investigation include: ADVAX (BIOLOGICAL).
Who is sponsoring clinical trial NCT00249106?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.